- Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) non-opioid painkiller.
- The company scrapped the ACP-044 program after evaluating the final phase 2 data on bunion removal patients.
- Initial data announced in April showed that the primary endpoint of pain intensity was not met.
- Rival Vertex boasted a mid-phase win for a similar candidate.
- Acadia has also discontinued ACP-319, which was tested in combination with Calquence in a phase 1 trial in relapsed/refractory chronic lymphocytic leukemia.
- In Acadia’s earnings report, the company hopes that trofinetide, submitted last month to the FDA for approval, will become the first treatment for a rare neurological condition called Rett syndrome.
- It also pointed to an in-house molecule called ACP-204, which is in phase 1 trials for neuropsychiatric indications. Acadia aims for ACP-204 to build upon its learnings garnered from the neuropsychiatric drug Nuplazid, the company’s only approved therapy to date.
- Price Action: ACAD shares are down 3.76% at $16.00 during the market session on the last check Tuesday.
Silgan Holdings Q3 Adj EPS $1.27 Beats $1.23 Estimate, Sales $1.97B Beat $1.84B Estimate
Silgan Holdings (NASDAQ:SLGN) reported quarterly Adjusted earnings of $1.27 per share which beat the analyst consensus estimate of $1.23 by 3.25 percent. This is a 24.51 percent increase over earnings of $1.02 per share
